GEFITINIB Side Effects

7011862-6 | Hepatic Function Abnormal
on Sep 14, 2010 Male patient from UNITED KINGDOM , 58 years of age, was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic function abnormal. Gefitinib dosage: . During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ).

6987621-7 | Vena Cava Thrombosis
Patient was taking Gefitinib (View Usage). Patient had the following side effects: vena cava thrombosis on Sep 07, 2010 from INDIA Additional patient health information: Female patient , 60 years of age, was diagnosed with gallbladder cancer (What is gallbladder cancer?) and. Gefitinib dosage: .

6802983-9 | Hepatitis
Adverse event was reported on Jun 18, 2010 by a Female patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer and. Location: JAPAN , 66 years of age, After Gefitinib was administered, patient had the following side effects: hepatitis (What is hepatitis?).

6755534-1 | Dyspnoea Exertional, Pneumonitis, Respiratory Failure
on May 31, 2010 Female patient from GERMANY , 65 years of age, was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea exertional, pneumonitis, respiratory failure. Gefitinib dosage: . Patient was hospitalized.


6737539-X | Cerebral Haemorrhage, Paronychia
on May 14, 2010 Male patient from CHINA , 75 years of age, was diagnosed with non-small cell lung cancer and was treated with Gefitinib (View Usage). Patient had the following side effects: cerebral haemorrhage, paronychia. Gefitinib dosage: .

6670966-8 | Haematuria, Hydronephrosis, Proteinuria
Patient was taking Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: haematuria, hydronephrosis, proteinuria on Mar 29, 2010 from JAPAN Additional patient health information: Female patient , 82 years of age, was diagnosed with non-small cell lung cancer, hypertension and. Gefitinib dosage: . During the same period patient was treated with NILVADIPINE (View Nilvadipine Review and Nilvadipine Label ). Patient was hospitalized.

6655110-5 | Haematuria, Hydronephrosis, Proteinuria
Adverse event was reported on Mar 18, 2010 by a Female patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer, hypertension and. Location: JAPAN , 82 years of age, Patient experienced the following unwanted or unexpected effects: haematuria, hydronephrosis, proteinuria. During the same period patient was treated with NILVADIPINE (View Nilvadipine Review and Nilvadipine Label ). Patient was hospitalized.

6647890-X | Rash, Skin Disorder
on Mar 15, 2010 Female patient from JAPAN , 69 years of age, was treated with Gefitinib (View Usage). Patient had the following side effects: rash (What is rash?), skin disorder. Gefitinib dosage: .

6617837-0 | Disseminated Intravascular Coagulation
on Mar 03, 2010 Female patient from CHINA , 66 years of age, was diagnosed with lung adenocarcinoma, metastases to central nervous system and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: disseminated intravascular coagulation. Gefitinib dosage: . During the same period patient was treated with MANNITOL (View Mannitol Review and Mannitol Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), NUTRITION SUPPORT (View Nutrition Support Review and Nutrition Support Label ).

6416693-3 | Apnoea, Brain Mass, Depressed Level Of Consciousness, Tumour Necrosis
Patient was taking Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: apnoea, brain mass, depressed level of consciousness, tumour necrosis on Oct 23, 2009 from SINGAPORE Additional patient health information: Male patient , 47 years of age, was diagnosed with non-small cell lung cancer, vasogenic cerebral oedema and. Gefitinib dosage: . During the same period patient was treated with STEROIDS (View Steroids Review and Steroids Label ). Patient was hospitalized.

6047108-5 | Rash, Subdural Haemorrhage
Adverse event was reported on Dec 05, 2008 by a Female patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer stage iv, hypertension, rash (What is rash?), gastrointestinal motility disorder, productive cough and. Location: KOREA, REPUBLIC OF , 75 years of age, Patient had the following side effects: rash (What is rash?), subdural haemorrhage. During the same period patient was treated with AMLODIPINE (View Amlodipine Review and Amlodipine Label ), AZELASTINE HCL (View Azelastine Hcl Review and Azelastine Hcl Label ), TRIMEBUTINE (View Trimebutine Review and Trimebutine Label ), AMBROXOL (View Ambroxol Review and Ambroxol Label ). Patient was hospitalized and became disabled.

5991502-5 | Rash, Subdural Haemorrhage
on Dec 05, 2008 Female patient from KOREA, REPUBLIC OF , 75 years of age, was diagnosed with non-small cell lung cancer stage iv, prophylaxis and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: rash (What is rash?), subdural haemorrhage. Gefitinib dosage: . During the same period patient was treated with AMLODIPINE (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

5876797-0 | Interstitial Lung Disease
on Sep 09, 2008 Male patient from JAPAN , 70 years of age, was diagnosed with lung adenocarcinoma and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease. Gefitinib dosage: .

5876795-7 | Interstitial Lung Disease
Patient was taking Gefitinib (View Usage). Patient had the following side effects: interstitial lung disease on Sep 09, 2008 from JAPAN Additional patient health information: Male patient , 71 years of age, was diagnosed with lung adenocarcinoma and. Gefitinib dosage: .

5753799-6 | Propionibacterium Infection
Adverse event was reported on May 28, 2008 by a Female patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with lung adenocarcinoma and. Location: FRANCE , 50 years of age, After Gefitinib was administered, patient had the following side effects: propionibacterium infection. Patient was hospitalized.

5750891-7 | Radiation Skin Injury, Subdural Haematoma
on May 20, 2008 Male patient from TAIWAN, PROVINCE OF CHINA , 57 years of age, was diagnosed with lung neoplasm malignant, adenocarcinoma, metastases to central nervous system and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: radiation skin injury, subdural haematoma. Gefitinib dosage: . During the same period patient was treated with ERLOTINIB (View Erlotinib Review and Erlotinib Label ).

5746747-6 | Propionibacterium Infection
on May 20, 2008 Female patient from FRANCE , 50 years of age, was diagnosed with lung neoplasm malignant and was treated with Gefitinib (View Usage). Patient had the following side effects: propionibacterium infection. Gefitinib dosage: . Patient was hospitalized.

5622193-0 | Myocardial Infarction, Neutropenic Sepsis
Patient was taking Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: myocardial infarction, neutropenic sepsis on Feb 07, 2008 from UNITED KINGDOM Additional patient health information: Male patient , weighting 136.7 lb, was diagnosed with non-small cell lung cancer, metastases to liver, pain (What is pain?), angina pectoris, dyspepsia, infection (What is infection?), haemoglobin decreased and. Gefitinib dosage: . During the same period patient was treated with DICLOFENAC (View Diclofenac Review and Diclofenac Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized and became disabled.

5601460-0 | Dermatosis
Adverse event was reported on Jan 21, 2008 by a Female patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with lung neoplasm malignant and. Location: TAIWAN, PROVINCE OF CHINA , 69 years of age, Patient experienced the following unwanted or unexpected effects: dermatosis.

5585422-8 | Myelodysplastic Syndrome
on Jan 07, 2008 Male patient from UNITED STATES , 72 years of age, was diagnosed with lung adenocarcinoma stage iv and was treated with Gefitinib (View Usage). Patient had the following side effects: myelodysplastic syndrome. Gefitinib dosage: Temporarily Stopped. During the same period patient was treated with GEMCITABINE (5 Cycles) (View Gemcitabine Review and Gemcitabine Label ), CARBOPLATIN (5 Cycles) (View Carboplatin Review and Carboplatin Label ).

5267862-X | Interstitial Lung Disease, Pulmonary Fibrosis
on Apr 25, 2005 Male patient from UNITED STATES , 59 years of age, was diagnosed with non-small cell lung cancer and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: interstitial lung disease, pulmonary fibrosis (What is pulmonary fibrosis?). Gefitinib dosage: 250 Mg Daily Po. During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

5267547-X | Interstitial Lung Disease, Pulmonary Fibrosis
Patient was taking Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease, pulmonary fibrosis (What is pulmonary fibrosis?) on Apr 25, 2005 from UNITED STATES Additional patient health information: Male patient , 55 years of age, was diagnosed with non-small cell lung cancer and. Gefitinib dosage: 250 Mg Daily Po. During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

5134677-2 | Metastases To Central Nervous System, Orthostatic Hypotension, Prescribed Overdose, Somnolence, Thrombocytopenia, Transaminases Increased
Adverse event was reported on Oct 16, 2006 by a Male patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with lung adenocarcinoma stage iv and. Location: UNITED STATES , 53 years of age, Patient had the following side effects: metastases to central nervous system, orthostatic hypotension, prescribed overdose, somnolence, thrombocytopenia, transaminases increased.

5121098-1 | Hypersensitivity, Metabolic Acidosis, Nephropathy Toxic, Pneumonia Aspiration, Renal Failure Acute
on Sep 25, 2006 Male patient from TAIWAN, PROVINCE OF CHINA , 73 years of age, was diagnosed with adenosquamous cell lung cancer and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: hypersensitivity, metabolic acidosis, nephropathy toxic, pneumonia aspiration, renal failure acute. Gefitinib dosage: . During the same period patient was treated with GEMCITABINE (4 Courses) (View Gemcitabine Review and Gemcitabine Label ), CISPLATIN (4 Courses) (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ).

4957592-3 | Diarrhoea, Dyspepsia, Hepatic Enzyme Increased, Hepatic Fibrosis, Hepatic Necrosis, Hepatitis, Rash Pruritic
on Nov 30, 2005 Female patient from CANADA , 57 years of age, was diagnosed with non-small cell lung cancer, pruritus, abdominal discomfort and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, dyspepsia, hepatic enzyme increased, hepatic fibrosis, hepatic necrosis, hepatitis (What is hepatitis?), rash pruritic. Gefitinib dosage: . During the same period patient was treated with CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ).

4951438-5 | Anaemia, Diarrhoea, Disease Progression, Intestinal Obstruction, Liver Function Test Abnormal, Overgrowth Bacterial, Pancreatic Insufficiency, Renal Failure, Somnolence
Patient was taking Gefitinib (View Usage). Patient had the following side effects: anaemia, diarrhoea, disease progression, intestinal obstruction, liver function test abnormal, overgrowth bacterial, pancreatic insufficiency, renal failure, somnolence on Jul 20, 2005 from UNITED KINGDOM Additional patient health information: Male patient , weighting 133.2 lb, was diagnosed with non-small cell lung cancer, analgesic effect, depression (What is depression?), insomnia, pain (What is pain?), muscle spasms and. Gefitinib dosage: . During the same period patient was treated with GABAPENTIN (View Gabapentin Review and Gabapentin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CARBAMAZEPINE (View Carbamazepine Review and Carbamazepine Label ), VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), HALOPERIDOL (View Haloperidol Review and Haloperidol Label ), BUSCOPAN (View Buscopan Review and Buscopan Label ). Patient was hospitalized.

4941031-2 | Anaemia, Diarrhoea, Intestinal Obstruction, Liver Function Test Abnormal, Malignant Neoplasm Progression, Non-small Cell Lung Cancer, Oral Intake Reduced, Overgrowth Bacterial, Pain
Adverse event was reported on Jul 20, 2005 by a Male patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer, analgesic effect, depression (What is depression?), insomnia, pain (What is pain?), muscle spasms and. Location: UNITED KINGDOM , weighting 133.2 lb, After Gefitinib was administered, patient had the following side effects: anaemia, diarrhoea, intestinal obstruction, liver function test abnormal, malignant neoplasm progression, non-small cell lung cancer, oral intake reduced, overgrowth bacterial, pain (What is pain?). During the same period patient was treated with GABAPENTIN (View Gabapentin Review and Gabapentin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CARBAMAZEPINE (View Carbamazepine Review and Carbamazepine Label ), VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), HALOPERIDOL (View Haloperidol Review and Haloperidol Label ), BUSCOPAN (View Buscopan Review and Buscopan Label ). Patient was hospitalized.

4928992-2 | Anaemia, Diarrhoea, Intestinal Obstruction, Liver Function Test Abnormal, Malignant Neoplasm Progression, Non-small Cell Lung Cancer, Overgrowth Bacterial, Pain, Pancreatic Insufficiency
on Jul 20, 2005 Male patient from UNITED KINGDOM , weighting 133.2 lb, was diagnosed with non-small cell lung cancer, analgesic effect, depression (What is depression?), insomnia, pain (What is pain?), muscle spasms and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, diarrhoea, intestinal obstruction, liver function test abnormal, malignant neoplasm progression, non-small cell lung cancer, overgrowth bacterial, pain (What is pain?), pancreatic insufficiency. Gefitinib dosage: . During the same period patient was treated with GABAPENTIN (View Gabapentin Review and Gabapentin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CARBAMAZEPINE (View Carbamazepine Review and Carbamazepine Label ), VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), HALOPERIDOL (View Haloperidol Review and Haloperidol Label ), BUSCOPAN (View Buscopan Review and Buscopan Label ). Patient was hospitalized.

4920025-7 | Anaemia, Diarrhoea, Disease Progression, Intestinal Obstruction, Liver Function Test Abnormal, Oral Intake Reduced, Pain, Renal Failure, Somnolence
on Jul 20, 2005 Male patient from UNITED KINGDOM , weighting 133.2 lb, was diagnosed with non-small cell lung cancer, analgesic effect, depression (What is depression?), insomnia, pain (What is pain?), muscle spasms and was treated with Gefitinib (View Usage). Patient had the following side effects: anaemia, diarrhoea, disease progression, intestinal obstruction, liver function test abnormal, oral intake reduced, pain (What is pain?), renal failure, somnolence. Gefitinib dosage: . During the same period patient was treated with GABAPENTIN (View Gabapentin Review and Gabapentin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CARBAMAZEPINE (View Carbamazepine Review and Carbamazepine Label ), VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), HALOPERIDOL (View Haloperidol Review and Haloperidol Label ), BUSCOPAN (View Buscopan Review and Buscopan Label ). Patient was hospitalized.

4917038-8 | Cardiotoxicity
Patient was taking Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: cardiotoxicity on Feb 08, 2006 from ITALY Additional patient health information: Female patient , 68 years of age, was diagnosed with breast cancer metastatic and. Gefitinib dosage: . During the same period patient was treated with EPIRUBICIN (Cumulative Dose Of 1140mg/m^2, 20 Min Infusion Once A Week) (View Epirubicin Review and Epirubicin Label ). Patient was hospitalized.

4902344-3 | Pulmonary Embolism
Adverse event was reported on Feb 02, 2006 by a Male patient taking Gefitinib (View Usage) (Dosage: 250mg Po Qd) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 160.9 lb, Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with AMBIEN (View Ambien Review and Ambien Label ), CLINDAMYCIN/BENZOYL PEROXIDE (View Clindamycin/benzoyl Peroxide Review and Clindamycin/benzoyl Peroxide Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ).

4876833-4 | Asthenia, Cardiopulmonary Failure, Fall, Hydrocephalus
on Dec 05, 2005 Male patient from UNITED STATES , 60 years of age, weighting 204.4 lb, was diagnosed with glioblastoma multiforme and was treated with Gefitinib (View Usage). Patient had the following side effects: asthenia, cardiopulmonary failure, fall (What is fall?), hydrocephalus (What is hydrocephalus?). Gefitinib dosage: . During the same period patient was treated with RAD 001 (View Rad 001 Review and Rad 001 Label ), GLUCOPHAGE (View Glucophage Review and Glucophage Label ), LIPITOR (View Lipitor Review and Lipitor Label ), REGLAN (View Reglan Review and Reglan Label ), DECADRON (View Decadron Review and Decadron Label ), ALTACE (View Altace Review and Altace Label ), COLACE (View Colace Review and Colace Label ), NIASPAN (View Niaspan Review and Niaspan Label ). Patient was hospitalized.

4851821-2 | Diarrhoea, Dyspepsia, Hepatic Enzyme Increased, Hepatic Fibrosis, Hepatic Necrosis, Hepatitis, Hepatocellular Damage, Rash Pruritic
on Nov 30, 2005 Female patient from CANADA , 57 years of age, was diagnosed with non-small cell lung cancer, pruritus, abdominal discomfort and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: diarrhoea, dyspepsia, hepatic enzyme increased, hepatic fibrosis, hepatic necrosis, hepatitis (What is hepatitis?), hepatocellular damage, rash pruritic. Gefitinib dosage: . During the same period patient was treated with CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ).

4850705-3 | Hydrocephalus
Patient was taking Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: hydrocephalus (What is hydrocephalus?) on Dec 05, 2005 from UNITED STATES Additional patient health information: Male patient , 60 years of age, weighting 204.4 lb, was diagnosed with glioblastoma multiforme and. Gefitinib dosage: . During the same period patient was treated with RAD 001 (View Rad 001 Review and Rad 001 Label ), GLUCOPHAGE (View Glucophage Review and Glucophage Label ), LIPITOR (View Lipitor Review and Lipitor Label ), REGLAN (View Reglan Review and Reglan Label ), DECADRON (View Decadron Review and Decadron Label ), ALTACE (View Altace Review and Altace Label ), COLACE (View Colace Review and Colace Label ), NIASPAN (View Niaspan Review and Niaspan Label ). Patient was hospitalized.

4849077-X | Dyspnoea, Fall, Fatigue
Adverse event was reported on Sep 29, 2004 by a Male patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with prostate cancer (What is prostate cancer?), angina pectoris and. Location: IRELAND , 65 years of age, weighting 187.4 lb, Patient had the following side effects: dyspnoea, fall (What is fall?), fatigue. During the same period patient was treated with DIFENE (View Difene Review and Difene Label ), ACETAMINOPHEN W/ CODEINE (View Acetaminophen W/ Codeine Review and Acetaminophen W/ Codeine Label ), TAMSULOSIN HCL (Ongoing At Study Start) (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), ATORVASTATIN CALCIUM (Ongoing At Study Start) (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), DOTHIEPIN HYDROCHLORIDE (Ongoing At Study Start) (View Dothiepin Hydrochloride Review and Dothiepin Hydrochloride Label ), ISOSORBIDE MONONITRATE (Ongoing At Study Start) (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), SALMETEROL/FLUTICASONE (Ongoing At Study Start) (View Salmeterol/fluticasone Review and Salmeterol/fluticasone Label ).

4808336-7 | Conjunctival Ulcer, Mucosal Ulceration, Tracheal Oedema
on Aug 15, 2005 Female patient from UNITED KINGDOM , weighting 127.9 lb, was diagnosed with non-small cell lung cancer and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: conjunctival ulcer, mucosal ulceration, tracheal oedema. Gefitinib dosage: .

4800219-1 | International Normalised Ratio Increased
on Oct 04, 2005 Female patient from JAPAN , 74 years of age, was diagnosed with bronchioloalveolar carcinoma, thrombosis prophylaxis and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: international normalised ratio increased. Gefitinib dosage: . During the same period patient was treated with WARFARIN (View Warfarin Review and Warfarin Label ).

4778057-8 | Convulsion, Disease Progression
Patient was taking Gefitinib (View Usage). Patient had the following side effects: convulsion, disease progression on Sep 23, 2005 from UNITED STATES Additional patient health information: Female patient , 42 years of age, weighting 132.3 lb, . Gefitinib dosage: 250mg. During the same period patient was treated with LOVENOX (View Lovenox Review and Lovenox Label ), ALEVE (View Aleve Review and Aleve Label ). Patient was hospitalized.

4760150-7 | Brain Oedema, Brain Scan Abnormal, Convulsion, Hemiparesis
Adverse event was reported on Aug 31, 2005 by a Male patient taking Gefitinib (View Usage) (Dosage: 250 Mg Po Weekly) was diagnosed with glioblastoma multiforme and. Location: UNITED STATES , 49 years of age, weighting 160.9 lb, After Gefitinib was administered, patient had the following side effects: brain oedema, brain scan abnormal, convulsion, hemiparesis. During the same period patient was treated with RAD 001 (70 Mg Po Weekly) (View Rad 001 Review and Rad 001 Label ), KEPPRA (View Keppra Review and Keppra Label ), ADVIL (View Advil Review and Advil Label ), TETRACYCLINE (View Tetracycline Review and Tetracycline Label ), COLACE (View Colace Review and Colace Label ), BENADRYL (View Benadryl Review and Benadryl Label ), CALCITRIOL (View Calcitriol Review and Calcitriol Label ), CELEBREX (View Celebrex Review and Celebrex Label ). Patient was hospitalized.

4753322-9 | Conjunctival Ulcer, Mucosal Ulceration, Tracheal Oedema
on Aug 15, 2005 Female patient from UNITED KINGDOM , weighting 127.9 lb, was diagnosed with non-small cell lung cancer and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: conjunctival ulcer, mucosal ulceration, tracheal oedema. Gefitinib dosage: .

4697272-5 | Dyspnoea Exacerbated, Performance Status Decreased, Pneumonia
on Mar 30, 2005 Male patient from , weighting 167.6 lb, was diagnosed with non-small cell lung cancer, pain (What is pain?), hypertension, gastritis and was treated with Gefitinib (View Usage). Patient had the following side effects: dyspnoea exacerbated, performance status decreased, pneumonia (What is pneumonia?). Gefitinib dosage: . During the same period patient was treated with IBUHEXAL (View Ibuhexal Review and Ibuhexal Label ), LISIGAMMA (View Lisigamma Review and Lisigamma Label ), RIFUN (View Rifun Review and Rifun Label ), TEPILTA (View Tepilta Review and Tepilta Label ). Patient was hospitalized.

4677982-6 | Dyspnoea, Fall, Fatigue
Patient was taking Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: dyspnoea, fall (What is fall?), fatigue on Sep 29, 2004 from Additional patient health information: Male patient , weighting 187.4 lb, was diagnosed with prostate cancer (What is prostate cancer?), angina pectoris and. Gefitinib dosage: . During the same period patient was treated with DIFENE (View Difene Review and Difene Label ), TYLEX (View Tylex Review and Tylex Label ), TAMSULOSIN (Ongoing At Study Start) (View Tamsulosin Review and Tamsulosin Label ), ATORVASTATIN (Ongoing At Study Start) (View Atorvastatin Review and Atorvastatin Label ), DOTHIEPIN HYDROCHLORIDE (Ongoing At Study Start) (View Dothiepin Hydrochloride Review and Dothiepin Hydrochloride Label ), ISOSORBIDE MONONITRATE (Ongoing At Study Start) (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), SALMETEROL/FLUTICASONE (Ongoing At Study Start) (View Salmeterol/fluticasone Review and Salmeterol/fluticasone Label ).

4677982-6 | Dyspnoea, Fall, Fatigue
Adverse event was reported on Sep 29, 2004 by a Male patient taking Gefitinib (View Usage) (Dosage: ) was diagnosed with prostate cancer (What is prostate cancer?), angina pectoris and. Location: IRELAND , 65 years of age, weighting 187.4 lb, Patient experienced the following unwanted or unexpected effects: dyspnoea, fall (What is fall?), fatigue. During the same period patient was treated with DIFENE (View Difene Review and Difene Label ), ACETAMINOPHEN W/ CODEINE (View Acetaminophen W/ Codeine Review and Acetaminophen W/ Codeine Label ), TAMSULOSIN (Ongoing At Study Start) (View Tamsulosin Review and Tamsulosin Label ), ATORVASTATIN (Ongoing At Study Start) (View Atorvastatin Review and Atorvastatin Label ), DOTHIEPIN HYDROCHLORIDE (Ongoing At Study Start) (View Dothiepin Hydrochloride Review and Dothiepin Hydrochloride Label ), ISOSORBIDE MONONITRATE (Ongoing At Study Start) (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), SALMETEROL/FLUTICASONE (Ongoing At Study Start) (View Salmeterol/fluticasone Review and Salmeterol/fluticasone Label ).

4673630-X | Circulatory Collapse, Interstitial Lung Disease
on May 19, 2005 Male patient from , 71 years of age, was diagnosed with squamous cell carcinoma and was treated with Gefitinib (View Usage). Patient had the following side effects: circulatory collapse, interstitial lung disease. Gefitinib dosage: . Patient was hospitalized.

4665452-0 | Ammonia Increased, Confusional State, Convulsion, Decreased Appetite, Dysphagia, Mental Status Changes
on May 18, 2005 Female patient from , 22 years of age, weighting 185.2 lb, was diagnosed with glioblastoma multiforme and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: ammonia increased, confusional state, convulsion, decreased appetite, dysphagia, mental status changes. Gefitinib dosage: 250 Mg Daily. During the same period patient was treated with RAD 001 (70 Mg Weekly) (View Rad 001 Review and Rad 001 Label ), DEPAKOTE (View Depakote Review and Depakote Label ), DAPSONE (View Dapsone Review and Dapsone Label ), PROTONIX (View Protonix Review and Protonix Label ), DECADRON (View Decadron Review and Decadron Label ). Patient was hospitalized.

4647772-9 | Dyspnoea, Pneumonia, Tumour Necrosis
Patient was taking Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, pneumonia (What is pneumonia?), tumour necrosis on Mar 30, 2005 from Additional patient health information: Male patient , 38 years of age, weighting 167.6 lb, was diagnosed with non-small cell lung cancer and. Gefitinib dosage: 250 Mg Daily; Po. During the same period patient was treated with IBUHEXAL (View Ibuhexal Review and Ibuhexal Label ), LISIGAMMA (View Lisigamma Review and Lisigamma Label ), RIFUN (View Rifun Review and Rifun Label ), TEPILTA (View Tepilta Review and Tepilta Label ). Patient was hospitalized.

4640056-4 | Asthenia, Diarrhoea, Dyspnoea, Feeling Hot, Haemoglobin Decreased, Influenza Like Illness, Malaise, Oral Pain, Pulmonary Mass
Adverse event was reported on Mar 30, 2005 by a Female patient taking Gefitinib (View Usage) (Dosage: 250 Mg Qd Po) was diagnosed with non-small cell lung cancer and. Location: , 70 years of age, Patient had the following side effects: asthenia, diarrhoea, dyspnoea, feeling hot, haemoglobin decreased, influenza like illness, malaise, oral pain, pulmonary mass. During the same period patient was treated with RANITIDINE (View Ranitidine Review and Ranitidine Label ), MELOXICAM (View Meloxicam Review and Meloxicam Label ), BENDROFLUAZIDE (View Bendrofluazide Review and Bendrofluazide Label ), CO DYDRAMOL (View Co-dydramol Review and Co-dydramol Label ).

4633257-2 | Dyspnoea, Performance Status Decreased, Pneumonia, Tumour Necrosis
on Mar 30, 2005 Male patient from , 38 years of age, weighting 167.6 lb, was diagnosed with non-small cell lung cancer and was treated with Gefitinib (View Usage). After Gefitinib was administered, patient had the following side effects: dyspnoea, performance status decreased, pneumonia (What is pneumonia?), tumour necrosis. Gefitinib dosage: 250 Mg Daily Po. During the same period patient was treated with IBUHEXAL (View Ibuhexal Review and Ibuhexal Label ), LISIGAMMA (View Lisigamma Review and Lisigamma Label ), RIFUN (View Rifun Review and Rifun Label ), TEPILTA (View Tepilta Review and Tepilta Label ). Patient was hospitalized.

4631503-2 | Glomerular Filtration Rate Decreased
on Mar 23, 2005 Male patient from , 58 years of age, was diagnosed with hypopharyngeal cancer and was treated with Gefitinib (View Usage). Patient experienced the following unwanted or unexpected effects: glomerular filtration rate decreased. Gefitinib dosage: . During the same period patient was treated with METHOTREXATE (40 Mg/m2 Week Iv) (View Methotrexate Review and Methotrexate Label ), CREON (View Creon Review and Creon Label ), DIHYDROCODEINE BITARTRATE INJ (View Dihydrocodeine Bitartrate Inj Review and Dihydrocodeine Bitartrate Inj Label ). Patient was hospitalized.

4629477-3 | Chest Pain, Diffuse Alveolar Damage, Lower Respiratory Tract Infection, Lung Consolidation, Pleuritic Pain, Pneumonia, Productive Cough, Respiratory Failure
Patient was taking Gefitinib (View Usage). Patient had the following side effects: chest pain (What is chest pain?), diffuse alveolar damage, lower respiratory tract infection, lung consolidation, pleuritic pain, pneumonia (What is pneumonia?), productive cough, respiratory failure on Mar 21, 2005 from Additional patient health information: Male patient , 58 years of age, weighting 215.0 lb, was diagnosed with non-small cell lung cancer and. Gefitinib dosage: 250 Mg Qd Po. During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), MST (View Mst Review and Mst Label ), FLUOXETINE (View Fluoxetine Review and Fluoxetine Label ), DIFFLAM (View Difflam Review and Difflam Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), ADCAL (View Adcal Review and Adcal Label ), FLUTICASONE PROPIONATE (View Fluticasone Propionate Review and Fluticasone Propionate Label ). Patient was hospitalized.